Fatty acid synthase (FASN) catalyzes the conversion of malonyl CoA and acetyl CoA to the saturated C16 fatty acid palmitate, which plays a key role in DNL, making this multi-catalytic protein an attractive therapeutic target for obesity, and associated liver diseases (265). The gene discussed is FASN; the disease is obesity due to melanocortin 4 receptor deficiency.